Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted Allogene Therapeutics’ (NASDAQ: ALLO) interim futility analysis from its registrational…
FairJourney Biologics Launches Cryo-EM Structural Biology Facility in San Diego FairJourney Bio (FJBio), a global contract research organization specializing in antibody discovery, has announced the opening of a cutting-edge cryo-electron microscopy (cryo-EM) structural biology facility in San Diego. The launch…
Bial Introduces Awareness and Education Initiative in Support of World Parkinson’s Day Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, has announced the launch of a major global awareness initiative titled “Dialogues with Parkinson’s” to mark World…
Vedanta Biosciences Highlights Advances in Microbiome-Based Therapeutics at ESCMID 2026 Global Congress Vedanta Biosciences, a late clinical-stage biopharmaceutical company focused on developing microbiome-based oral therapies for gastrointestinal diseases, has announced its participation in the upcoming European Society of Clinical Microbiology…
TAE Life Sciences Highlights Breakthrough BNCT Research Showing Sustained Tumor Control and Systemic Immune Effects TAE Life Sciences has announced the publication of new preclinical research in ACS Pharmacology & Translational Science, highlighting significant advancements in its next-generation boron delivery…
Aurion Biotech Initiates Dosing in Phase 3 ASTRA Study Evaluating AURN001 for Corneal Edema Secondary to Corneal Endothelial Dysfunction Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company focused on restoring vision and addressing corneal blindness, has announced…
CaryHealth Introduces Direct-to-Patient Access Program for Natroba in Collaboration with Cipher Pharmaceuticals CaryHealth, a leading provider of integrated digital healthcare solutions, has announced the launch of a new direct-to-patient (DTP) platform aimed at improving access to prescription treatments for common…
Amgen Shares Positive Topline Phase 3 Data for Subcutaneous TEPEZZA® in Adults with Moderate-to-Severe Active Thyroid Eye Disease Amgen (NASDAQ: AMGN) has announced positive topline results from a pivotal Phase 3 clinical trial evaluating a new method of administering TEPEZZA…
PureTech Reports Publication of Phase 2b ELEVATE IPF Trial Results in Leading Respiratory Medicine Journal PureTech Health plc, a clinical-stage biotherapeutics company focused on translating cutting-edge science into transformative therapies, has announced the publication of results from its Phase 2b…
Glycomine Announces Completion of Enrollment in Global Phase 2b POLAR Study Evaluating GLM101 for PMM2-CDG Glycomine, Inc. has announced the successful completion of patient enrollment in its Phase 2b POLAR clinical trial, a key milestone in the development of GLM101…
Vedanta Biosciences Confirms Phase 3 RESTORATiVE303 Study of VE303 Will Proceed as Planned Following Interim Analysis Vedanta Biosciences, a late clinical-stage company focused on developing microbiome-based oral therapies for gastrointestinal diseases, has announced encouraging progress in its pivotal Phase 3…
Thermo Fisher Scientific Introduces Unified Platform to Speed Biologics Development Thermo Fisher Scientific Inc., a global leader in scientific services and life sciences solutions, has introduced a next-generation, integrated cell line development (CLD) platform designed to accelerate biologics development timelines…